Zhan, "Suppressing H19 modulates tumorigenicity
and stemness in U251 and U87MG glioma cells," Cellular and Molecular Neurobiology, vol.
, major histocompatibility antigens, and karyotypes of interspecific hybrids between mouse neuroblastoma and rat glioma or liver cells," Cancer Genetics and Cytogenetics, vol.
De Santis et al., "Lysophosphatidic acid receptor LPAR6 supports the tumorigenicity
of hepatocellular carcinoma," Cancer Research, vol.
Caption: Figure 2: In vivo tumorigenicity
of the three sHCC cell lines, sHCC29, sHCC63, and sHCC74, in NOD/SCID mice.
microRNA-195 promotes apoptosis and suppresses tumorigenicity
of human colorectal cancer cells.
(1) This reaction is involved in imported physiological and pathological processes such as respiration, transport of C[O.sub.2], pH and C[O.sub.2] homeostasis, some biosynthetic reactions, calcification and tumorigenicity
These miRs in the advanced stage may also migrate to osteoclast where they may produce a beneficial effect but its mechanism of action is still unclear to date.10,16 Evidence indicates that miR-16 can modulate the cell cycle, inhibit cell proliferation, promote cell apoptosis and suppress tumorigenicity
both in vivo and in vitro.
 Torres, M.P., Rachanagani, S., Purohit, V., Pandey, P., Joshi, W., Moore, E.D., Johansson, S.L., Singh, P.K., Ganti, A.K., Batra, S.K., "Graviola: A novel promoting natural derived drug that inhibits tumorigenicity
and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell meta olism" Journal of Cancer Letters, 323: 29-40(2012).
, logP, solubility, overall drug likeness and drug score in search of better drug candidate for experimental synthesis and applications [8, 9].
Graviola: a novel promising natural-derived drug that inhibits tumorigenicity
and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell metabolism.
More recently, TSPO has been shown to be part of the mitochondria-to-nucleus signaling pathway that modulates nuclear gene expression and TSPO levels have been directly correlated with increased tumorigenicity
and/or malignancy, probably as a mechanism to promote apoptosis and reduce tumorigenicity
, thereby suggesting that benign tumors do not have increased TSPO levels [6, 24-26].
Oncogenic-driven cancer cells generate increased ROS as by-products of their metabolism to maintain tumorigenicity